Subject: Specialty Quantity Limit Mektovi 2614-H P2023

Drug

MEKTOVI  (binimetinib)

Policy:

      I.  PROGRAM DESCRIPTION

          The standard limit is designed to allow a quantity sufficient for
          the most common uses of the medication. The recommended
          dosing parameters for all FDA-approved indications fall within
          the standard limits. Coverage of an additional quantity may be
          reviewed on a case-by-case basis upon request.

 
    II.  COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Mektovi   (binimetinib)   15 mg tablets	180 per 30 days	Initial dose: 45 mg (three 15 mg tablets)   twice daily     Dose adjustment for adverse reactions   or moderate or severe hepatic   impairment: 30 mg (two 15 mg tablets)   twice daily

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Mektovi [package insert]. Boulder, CO: Array BioPharma, Inc.; October 2020.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 15, 2023